Tightening our understanding of intensive glycaemic control

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 6, 2017, Pages 405-407

  Herrington, William G ^a   Preiss, David ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE ASSOCIATION; DISEASE SEVERITY; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; INTENSIVE GLYCEMIC CONTROL; LONG TERM CARE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA;

BLOOD GLUCOSE; HUMANS; HYPERGLYCEMIA;

EID: 85016479722     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30095-5     Document Type: Note

References (10)

1. Turnbull, FM, Abraira, C, Anderson, RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52 (2009), 2288–2298.
2. Zoungas, S, Arima, H, Gerstein, HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes & Endocrinol, 2017 published online March 29. http://dx.doi.org/10.1016/S2213-8587(17)30104-3.
3. American Diabetes Association. Glycemic targets. Diabetes Care 38:suppl 1 (2015), S33–S40.
4. Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group. Persistent effects of intensive glycemic control on retinopathy in type 2 diabetes in the action to control cardiovascular risk in diabetes (ACCORD) follow-on study. Diabetes Care 39 (2016), 1089–1100.
5. Zoungas, S, Chalmers, J, Neal, B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 371 (2014), 1392–1406.
6. Holman, RR, Paul, SK, Bethel, MA, Matthews, DR, Neil, HA, 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008), 1577–1589.
7. Hayward, RA, Reaven, PD, Emanuele, NV, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med, 373, 2015, 978.
8. Wanner, C, Inzucchi, SE, Lachin, JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
9. Marso, SP, Daniels, GH, Brown-Frandsen, K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
10. Evaluation of the effects of canagliflozin on renal and cardiovascular outcomes in participants with diabetic nephropathy (CREDENCE). https://clinicaltrials.gov/ct2/show/NCT02065791 (accessed Feb 10, 2017).